Melatonin Targeting Non-Coding Rnas in Cancer: Focus on Mechanisms and Potential Therapeutic Targets Publisher Pubmed



Mafi A^{1, 2} ; Keshavarzmotamed A³ ; Hedayati N⁴ ; Yeganeh Boroujeni Z⁵ ; Reiter RJ⁶ ; Mousavi Dehmordi R^{1, 7} ; Aarabi MH¹ ; Rezaee M^{8, 9} ; Asemi Z¹⁰ Show Affiliations
Source: European Journal of Pharmacology Published:2023

Abstract

Despite, melatonin is mainly known as a regulatory factor for circadian rhythm, its notable role in other fundamental biological processes, such as redox homeostasis and programmed cell death, has been found. In this line, a growing body of evidence indicated that melatonin could apply an inhibitory effect on the tumorigenic processes. Hence, melatonin might be considered an efficient adjuvant agent for cancer treatment. Besides, the physiological and pathological functions of non-coding RNAs (ncRNAs) in various disease, particularly cancers, have been expanded over the past two decades. It is well-established that ncRNAs can modulate the gene expression at various levels. Thereby, ncRNAs can regulate the numerous biological processes, including cell proliferation, cell metabolism, apoptosis, and cell cycle. Recently, targeting the ncRNAs expression provides a novel insight in the therapeutic approaches for cancer treatment. Moreover, accumulating investigations have revealed that melatonin could impact the expression of different ncRNAs in a multiple disorders, including cancer. Therefore, in the precent study, we discuss the potential roles of melatonin in modulating the expression of ncRNAs and the related molecular pathways in different types of cancer. Also, we highlighted its importance in therapeutic application and translational medicine in cancer treatment. © 2023 Elsevier B.V.